High-speed Ultrahigh Resolution Optical Coherence Tomography before and after Ranibizumab for Age-related Macular Degeneration
- 31 May 2009
- journal article
- Published by Elsevier BV in Ophthalmology
- Vol. 116 (5), 956-963
- https://doi.org/10.1016/j.ophtha.2008.12.018
Abstract
No abstract availableKeywords
Funding Information
- National Science Foundation (BES-0522845)
- National Institutes of Health (P30-EY008098, R01-EY11289-21, R01-EY13178-07)
- Air Force Office of Scientific Research (FA9550-07-1-0101)
This publication has 20 references indexed in Scilit:
- Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1American Journal of Ophthalmology, 2008
- PREDICTED BIOLOGIC ACTIVITY OF INTRAVITREAL BEVACIZUMABRetina, 2007
- Optical Coherence Tomography Identification of Occult Choroidal Neovascularization in Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2007
- Anti-VEGF Agents in the Treatment of Neovascular Age-related Macular Degeneration: Applying Clinical Trial Results to the Treatment of Everyday PatientsAmerican Journal of Ophthalmology, 2007
- An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2007
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- In vivo demonstration of the anatomic differences between classic and occult choroidal neovascularization using optical coherence tomographyAmerican Journal of Ophthalmology, 2005
- Sensitivity advantage of swept source and Fourier domain optical coherence tomographyOptics Express, 2003
- Performance of fourier domain vs time domain optical coherence tomographyOptics Express, 2003
- Optical Coherence TomographyScience, 1991